Collegium Pharmaceutical (NASDAQ:COLL) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Monday, Zacks.com reports. The brokerage presently has a $19.00 price target on the specialty pharmaceutical company’s stock. Zacks Investment Research‘s price objective would indicate a potential upside of 29.60% from the company’s previous close.
According to Zacks, “Collegium Pharmaceutical Inc. is a specialty pharmaceutical company. It develops and commercializes prescription and over-the-counter pharmaceuticals for the treatment of central nervous system, respiratory and skin related disorders. The Company’s product candidate consists of COL-195, COL-196, COL-171, COL-003 and COL-172 which are in different clinical trial. It developed a formulation platform technology, DETERx, for the treatment of chronic pain. Collegium Pharmaceutical Inc. is based in CUMBERLAND, United States. “
COLL has been the subject of several other reports. Cantor Fitzgerald set a $35.00 price objective on shares of Collegium Pharmaceutical and gave the stock a “buy” rating in a report on Friday. SunTrust Banks initiated coverage on shares of Collegium Pharmaceutical in a report on Tuesday, March 19th. They set a “buy” rating and a $22.00 target price for the company. ValuEngine lowered shares of Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a report on Tuesday, February 12th. Finally, BidaskClub upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating in a report on Wednesday, March 6th. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $28.67.
COLL traded down $1.93 on Monday, hitting $14.66. The company had a trading volume of 618,302 shares, compared to its average volume of 442,423. The company has a debt-to-equity ratio of 0.11, a current ratio of 1.26 and a quick ratio of 1.21. Collegium Pharmaceutical has a 52-week low of $13.10 and a 52-week high of $28.91. The firm has a market capitalization of $553.61 million, a PE ratio of -12.32 and a beta of 0.32.
Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings data on Wednesday, February 27th. The specialty pharmaceutical company reported $0.27 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.38) by $0.65. Collegium Pharmaceutical had a negative net margin of 13.95% and a negative return on equity of 41.12%. The business had revenue of $73.40 million during the quarter, compared to analyst estimates of $72.71 million. During the same period last year, the business posted ($0.54) earnings per share. Collegium Pharmaceutical’s quarterly revenue was up 579.6% compared to the same quarter last year. Analysts expect that Collegium Pharmaceutical will post -0.25 EPS for the current fiscal year.
In other news, Director Michael Thomas Heffernan sold 25,000 shares of Collegium Pharmaceutical stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $17.17, for a total transaction of $429,250.00. Following the completion of the transaction, the director now directly owns 227,362 shares in the company, valued at $3,903,805.54. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 75,000 shares of company stock valued at $1,188,500 over the last quarter. Company insiders own 8.08% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the company. Meeder Asset Management Inc. increased its position in shares of Collegium Pharmaceutical by 644.8% during the fourth quarter. Meeder Asset Management Inc. now owns 3,672 shares of the specialty pharmaceutical company’s stock valued at $62,000 after acquiring an additional 3,179 shares in the last quarter. Oregon Public Employees Retirement Fund bought a new stake in shares of Collegium Pharmaceutical during the fourth quarter valued at approximately $103,000. Metropolitan Life Insurance Co. NY increased its position in shares of Collegium Pharmaceutical by 412.6% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 11,124 shares of the specialty pharmaceutical company’s stock valued at $191,000 after acquiring an additional 8,954 shares in the last quarter. Advisory Services Network LLC bought a new stake in shares of Collegium Pharmaceutical during the fourth quarter valued at approximately $203,000. Finally, IHT Wealth Management LLC bought a new stake in shares of Collegium Pharmaceutical during the fourth quarter valued at approximately $219,000.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving.
Featured Story: What is the Consumer Price Index (CPI)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.